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Summary
Tolerance to alloantigen may be induced in rats by administration of blood followed by
transplantation of a renal allograft. The mechanism of this tolerance was investigated by directly
analyzing the functional activity of graft-infiltrating cells. We have previously shown cytotoxic
T lymphocyte infiltration of, and major histocompatibility complex induction on, grafts of tolerant
animals. We now report that cells isolated from the grafts oftolerant rats show a reduced expression
of the p55 interleukin 2 receptor (IIr2R) chain on the cell surface compared with that seen on
the cells of untreated animals. Scatchard analysis further reveals low expression of high affinity
IIr2R. This is due to reduced transcription of both IL2R cx and /3 chain mRNAs and results
in a reduced ability of cells to proliferate in response to IL2. Cells isolated from tolerant animals
are unable to make biologically active IL-2 in culture, whereas cells from untreated animals make
high levels. This is not reflected at the mRNA level as the IL2 gene is induced in both tolerant
and untreated animals to similar levels. The induction of tolerance is abrogated by administration
of recombinant IL2 to animals at the time oftransplantation. Thus, we conclude that an altered
regulation of the IL2 pathway results in tolerance in these alloantigen-treated and transplanted
animals.
I
nterleukin 2 plays a central role in amplification of immune
responses. Further, it has been suggested that an absence
of IL -2 and/or other cytokines after antigenic stimulation may
be critical in the induction of T and B cell anergy (1, 2).
Tolerance to antigens that are expressed within the thymus
usually results from deletion of autoreactive cells (3-5), al-
though recent evidence suggests that self-reactive cells may
escape deletion and become anergic (6, 7). Tolerance to an-
tigens expressed extrathymically does not seem to involve de-
letion but may result from the induction of anergy in the
autoreactive population(8-10). Tolerance to alloantigens may
be induced in adult animals by a single intravenous injection
of alloantigen in the form of whole blood (11). In the DA-
RT11 (DA)-PVG-RT1c (PVG) rat strain combination, in-
travenous administration of 1 ml whole DA blood to PVG
animals 7 d before transplantation of a DA kidney leads to
indefinite graft survival which is blood donor specific (12).
Indeed, these pretreated and transplanted animals may be re-
transplanted with a cardiac allograft of the same donor strain,
100 d after the primary graft, and the secondary graft also
survives indefinitely (our unpublished results). Thus, these
animals are tolerant ofthe original alloantigens. We and others
have investigated this transplantation tolerance by analyzing
immune events within the transplanted graft and have demon-
strated that the tolerance exists despite the presence of cells
reactive with donor alloantigen. Animals contain, in their
grafts and peripheral lymphoid organs, fully differentiated,
donor-specific, effector cytotoxic cells (12, 13) and can pro-
duce at least some cytokines as reflected by an induced level
ofboth MHC classI and II antigens on the transplanted tissue
(13, 14). Clearly then, this tolerance is not maintained by
a complete deletion of alloantigen-specific T cells. We have
now examined the status of the IL-2 pathway in these rats
by a direct analysis of intragraft events. Here we present evi-
dence that transplantation tolerance in this model is due to
an altered regulation of the recipient's IL-2 pathway that is
induced following rechallenge with alloantigen in the form
ofa transplant. Graft infiltrating cells isolated from tolerant
animals do not make biologically active IL-2, although ex-
pression ofthe IL-2 gene is induced, and do not respond nor-
mally to IL-2. This poor response to IL-2 is due to decreased
expression of both cz and 0 chains of the IL-2R. Further,
this tolerant statecan be reversed completely by administering
IL2 at the time of transplantation. These data suggest that,
in this model, a state of anergy has developed in the T cells
responsible for IL-2 production resulting in transplantation
tolerance.
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Animals.
￿
Inbred Lewis-RT11 (LEW), blood group D Agouti-
RTl' (DA), and PVG-RTI° (PVG) male rats were obtained from
Harlan Olac UK Ltd. (Bicester, UK) or bred in the Biomedical
Services Unit at the John Radcliffe Hospital (Oxford, UK).
Transfusion andTransplantation.
￿
DA rats were given1.0 ml PVG
(donor-specific) blood, intravenously, 7 dbefore transplantationof
a PVG or DA kidney. Control animals were either given 0.5 ml
LEW (third party) blood intravenously or nothing. Kidneys were
transplanted into theleft orthotopic site as previously described (15).
Preparation ofCell Suspensions.
￿
Kidneys were removed 3 or 5 d
after transplantation and digested with collagenase as previously
described (12) to releaseinfiltrating leukocytes. LN were removed
andlymphocytes teased into asingle-cell suspension through awire
mesh.
Flow Cytometry.
￿
Single-cell suspensions of graft-infiltrating cells
were stained at 4°C for 60 min with the following antibodies in
theform oftissueculture supernatant:MRCOXIandMRC OX30
(leukocyte-common antigen); NDS 61, NDS66, and MRC OX
39 (IL2Rp55, a chain); or MRC OX 21 (human Factor I). After
washing, cells were incubated with FITC-conjugated goat
anti-mouse Ig (F0257; Sigma Chemical Co., Poole, England).
Samples were analyzed on a flow cytometer (Ortho Diagnostic
Systems, Inc., Westwood, MA). Antibodies designated NDS were
produced in this laboratory (16); hybridomas producingantibodies
designated MRCOX andW3/25were kind giftsofDr. A.F. Wil-
liams(Medical Research Council Cellular Immunology Unit, Ox-
ford, England).
Scatchard Analysis.
￿
IL-2 was labeled with [1251]sodium iodide
usingEnzymobeads (170-6001; Bio-Rad, Hemel Hempstead, UK)
according to the manufacturer's methods to a specific activity of
2.04-2.16 x 10' cpm/p.g. Radiolabeled IL2 binding was per-
formed according to the slightly modified (17) method of Robb
et al. (18) . Briefly, graft-infiltrating cellswere resuspended in IL-2-
free RPMI (Gibco Ltd., Uxbridge, UK) for 2 h at 37°C. Serial
dilutions of radiolabeled 11,2 (in the range of 50 pM to 50 nM)
were added to 1.6 x 106 cells in a total volume of 500 Al RPMI
containing 0.1% BSA and 0.1% NaN3 andincubated at 20°C for
40 min. Free and cell-bound 1251-IL2 was separated by centrifu-
gation over a20% olive oil/80% dibutylphthalate mix. Cell pellets
were counted. Nonsaturable binding wasdetermined by incubating
cellswith a 100-1,000-fold excess ofunlabeled 11,2. Specific binding
was determined by subtracting nonsaturablebinding. Scatchardanal-
ysis was used to determine the presence of low and high affinity
11,2 binding sites.
11,2 Proliferation Assays.
￿
Cells were incubated at 5 x 105/ml
in RPMI containing 10% FCS, 2 mM glutamine, 2.5 x 10-5 M
2-ME and penicillin (45 Ag/ml), streptomycin (45 NAg/ml), and
kanomycin (90,ug/ml) (R10)in a totalvolume of 200Al in round-
well plates for 24 h at 37°C. 1 p,Ci ['H]thymidine was added to
each well for thelast 4 h of culture. Human rIL2 (a generous gift
of the Cetus Corp., Emeryville, CA) was added to the cultures
at the concentrations indicated.
IL2 Production Assays.
￿
7.5 x 105 graft-infiltrating leukocytes
were incubatedwith 7.5 x 105 irradiated (2,500 rad) DA rat LN
cells in a total volume of 1 ml in 24-well plates for 3 d at 37°C.
Supernatants of such cultures were then harvested and incubated
at various dilutions in 96-flat well plates for48 hwith an 11,2-de-
pendent rat cell line (developed in this laboratory) at 8 x 105
cells/ml in R10. During the final 4 h of culture, 1 uCi [3H]thymi-
dine was added per well. rIL2 was used as a positive control.
Preparation ofRNA andNorthern Blotting.
￿
Kidneyswere removed
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and immediately homogenized in guanidine thiocyanate solution
(4 M guanidine thiocyanate, 25 mM Na3 citrate, 0.2% sarkosyl,
200 mM 2-ME). Total RNA from individual rats was pelleted
through acesium chloride gradient (5.7 MCsCl, 100rnMEDTA).
10 p.g total RNA was denatured by glyoxal treatment (50°C, 60
min in 10 mM sodium phosphate, pH 7.0, 50% DMSO, 17%
deionized glyoxal; 26107; BDH Chemicals Ltd., Atherstone, En-
gland) andsize fractionated on a0.6%agarose gel. RNAwas trans-
ferred to nylon membranes (Hybond N RPN 303N; Amersham
International, Amersham, UK), fixedunder UV illumination and
hybridized to [tx-'ZP]dCTP-labeled cDNA probes in 50% forma-
mide, 6 x SSPE, 0.1% SDS, 0.25% Cadbury's Marvel. cDNA
probes for theIL2 Rat and 0 chains were prepared in this labora-
tory (Page, TH., andM.J. Dallman, manuscript submittedforpub-
lication).
Polymerase Chain Reaction (PCR).
￿
PCR was performed essen-
tially as previously described (19). Briefly, 1 jig total RNA was
incubated for 5 min at 60°C with 4pg oligo(dT) (27 7858; Phar-
macia, Milton Keynes, UK), chilled on ice for 3 min, and further
incubatedfor40 minat 37°C with 1 al RNAsin (799-017; BCL,
UK), 1 mM dNTPs, 400 U reverse transcriptase (murineMolony
leukemia virus, 510-8025; Gibco Ltd., Uxbridge, England) and 8
Al RT buffer (Gibco Ltd.). After 40 min, a further 400 U reverse
transcriptase was addedand incubated for 40 min at 37°C. Reac-
tionswere then heat inactivated at 70°C for 10min and 60 pl water
wasaddedpersample. PCRs were setup using 5 pi of this cDNA.
To this wasadded(finalconcentrations in parentheses) KCl(0.15 M),
Tris HCl, pH 8.3 (10 mM), MgC12 (1.5 mM), gelatin (0.01%),
dNTPs (0.2 mM each), primer Aand primer B (1 p,M each), and
2.5 UTaqpolymerase (N801-0046; Perkin-Elmer Corp., Hayward,
CA) in a total volume of 100 pl. This was overlaid with 50 pl
mineraloil (M3516; SigmaChemical Co.) . Primer sequenceswere
derived from the previously published mouse 11,2 sequence (20) .
We have found that theseprimers amplify a 0.4-kb product from
rat IL-2-producing cells whose sequence is identical to that of the
recently published rat 11,2 sequence (21). Primers A and B have
the sequences 5'AACAG000ACCCACTTCAA3' and 5'TTGA-
GATGATGCTTTGACA3'respectively. Samples were incubatedat
93°C for 1 min, 60°C for 2 min, and at 72°C for 1 min. This
cyclewasrepeated 20-60times usingaDNAthermalcycler (Perkin-
ElmerLtd., Beaconsfield, England). Controlprimers were derived
from the ratcytoplasmic 0-actin sequence and have the sequences
5'ATGGATGACGATATCGCTG3'and 5'ATGAGGTAGTCTGTC-
AGGT3'. PCR using these primers was as described for the 11,2
primers except that the reactions contained 2.5 mm MgC12 and
the annealing cycle wasperformed at 55°C. Sampleswere analyzed
either by gel electrophoresis, using 15-IAI samples of the amplified
DNA or by dotblot. Fordot blot analysis 151Al of the PCR mix
was removed after varying numbers of cycles, dot-blotted on to
nitrocellulose membrane (BA85; Schleicher & Schull, Anderman
and Co., Ltd., Kingston-Upon-Thames, England) and hybridized
to -y-[32P]ATP, end-labeled oligonucleotides whose positions in the
cDNA are internal to that of the original 2 primers and whose
sequences are 5'CACTGAAGATGTTTC3' and 5'AGCAAGAG-
AGGTATCCT3' for 11,2 and actin, respectively.
Treatment ofTransplanted Animalswith rIL2.
￿
Animals were trans-
fusedandtransplanted as described above. On thedayoftransplan-
tation and for thesubsequent 5d, animals received an intraperitoneal
injectionof rIL2 diluted in RPMI containing 10% FCS and anti-
biotics. 7 d after transplantation, the animals' second kidney was
removedso that survival of theanimal depended on adequate func-
tion of the transplanted kidney.g 2 0TOLERONT L-C
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The Cell Surface Expression ofII,2R Is Reduced on Graft-
infiltrating Cellsfrom Tolerant Animals. We have previously
described that the leukocyte infiltration is similar in grafts
from tolerant and untreated (nontolerant) animals (14) . The
expression of 11,2 receptors on graft-infiltrating cells was ex-
amined phenotypically by flow cytometry and Fig. 1 shows
an analysis of the cells from one tolerant (a-c) and one non-
tolerant (dj) animal. Cells in both types of graft express the
IL2R. However, although the percentage of leukocytes ex-
pressing the IL2R was similar in tolerant and nontolerant
animals (means of34.1 and 37% for six and for four animals,
respectively), the level of expression of the receptor, asjudged
by the mean channel fluorescence, was consistently reduced
on cells from tolerant animals (means of 400 and 271 on the
cells of untreated [four rats] and tolerant [six rats] animals,
respectively; Fig. 1, b and e). Since the antibodies used for
this phenotypic analysis only react with the p55, ot chain,
of the rat IL2R, Scatchard analysis was used to examine the
expression ofhigh affinity IL2R, which require the presence
of both ct and S chains. This analysis revealed a lack of ex-
pression of high affinity IL2 binding to the cells from tolerant
rats (Fig. 2, a and b).
II,2R cz- and a-Chain GenesAre Weakly Expressed in Tolerant
Animals. Northern analysis using total RNA isolated from
the grafts of tolerant rats shows that IL2R cx-chain gene is
barely expressed, whereas strong expression is seen in grafts
of nontolerant animals (Fig. 3 a) . This result suggests that
the low surface expression of the IL-2R a chain by leuko-
cytes from the tolerant animals was due to a weak induction
of the gene. The IL2R S chain gene is constitutively ex-
pressed by rat T cells although its expression is upregulated
upon activation (Page, T.H., and M.J. Dallman, manuscript
submitted for publication). Fig. 3 b shows that although IL
2R (3-chain mRNA is seen in the grafts of both tolerant and
nontolerant animals it is expressed at a higher level in those
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Figure 1.
￿
Graft-infiltrating
cells from tolerant rats express low
levels of the II,2R a chain. Cells
were obtained from the transplants
of one tolerant (a-c) and one non-
tolerant (d-f) animal 5 d after
grafting, by collagenase digestion of
the grafts, and examined for surface
expression of the II,2R by flow
cytometry. Percentage of cells
stained with antibodies against leu-
kocyte common antigen, ITC (a and
d; MRC OXI+MRC OX30); IL
2R (b and e; NDS61+NDS66+
MRC OX39); or human Factor I
(c andf ; MRC OX21, negativecon-
trol) is shown with mean channel
fluorescence (as an indication oflevel
ofexpression) ofIIL2R-positivecells
(mcf). These data are examples from
single animals; mean results from
groups of animals are given in the
text.
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Figure 2.
￿
The presence ofhigh and low affinity IL2 binding sites on
graft-infiltrating cells from nontolerant (a; O) and tolerant (b; ") rats
was investigated using "Habeled IL2. Graft-infiltrating cells were re-
covered, 5 d after grafting, by collagenase digestion of the transplants,
and incubated with serial dilutions ofradiolabeled IL2. Free and cell-bound
11,2 were separated by centrifugation through oil, and cell pellets were
counted. Scatchard analysis was used to determine the presence of low
and high affinity IL2 binding sites. The experiment was repeated with
similar results.Figure 3 .
￿
IIr2R a and S chain genes are weakly expressed in tolerant
animals. TotalRNA was isolated from grafts in tolerant (T) or nontolerant
(NT) animals 1, 3, or 5 d after renal transplantation . 10 p.g total RNA
was subjected to Northern analysis and probed with cDNA probes for
the rat ILr2R a (a) or /3 (b) chain. c shows theRNA stained with ethidium
bromide to show equal loading ofall samples. TheseRNA samples were
also used for experiment shown in Fig . 8 . This experiment was repeated
with essentially the same result .
82
of nontolerant animals . NK cells have been reported to ex-
press the IIr2R /3 chain (22) . The higher level of expression
of the O-chain gene by untreated rats is, however, unlikely
to be due to increased infiltration by NK cells since NK ac-
tivity is similar in the grafts oftolerant and nontolerant animals
(reference 13, and our unpublished observations) . These data
indicate, therefore, that low expression of not only the IIr
2R a chain gene but also of the a chain gene contributes
to the reduced level of high affinity IIT2 binding sites on the
graft-infiltrating cells of tolerant animals.
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￿
Graft-infiltrating cells from tolerant rats do not respond nor-
mally to 11,2 . Cells isolated from renal transplants were tested for their
ability to proliferate in response to 11,2 in a [3HJTdR uptake assay. Prolifer-
ation (cpm X 10-3 incorporated) of cells from grafts of untreated rats
(A) and alloantigen-pretreated rats (A) 5 d (a) or 3 d (b) after transplant .
Each titration represents the results from an individual animal. The ex-
periment was repeated three times with similar results.Cellsfrom Tolerant Animals Do Not Develop a Normal Re-
sponse to 11,2. Since the cells from tolerant animals express
low levels of the high affinity IIT2R, it seemed likely that
they would not be capable ofproliferating in response to IL
2 . Fig. 4 a shows that the cells isolated from the grafts of
tolerant animals, 5 d after transplantation, responded very
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￿
Rats pretreated with third-party blood develop a normal re-
sponse to 11,2 . Cells isolated from renal transplants were tested for their
ability to proliferate in response to IL2 in a [3H]TdR uptake assay. Prolifer-
ation (cpm x 10-3 incorporated) of cells from grafts ofthird-party blood-
treated animals (0) and donor-specific blood-treated rats (" ) either 5 d
(a) or 3 d (b) after transplant . Each titration represents the results from
an individual animal . The experiment was repeated with essentially the
same result .
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Figure 6 .
￿
Graft-infiltrating cells from tolerant rats are unable to make
biologically active 11,2 . Leukocytes isolated from allografts of tolerant (A)
and nontolerant (0) animals, 3 d after transplantation, were restimulated
with alloantigen in vitro . The supernatants from such cultures were as-
sayed for 11,2 activityusing an U,2-dependent ratcell line. rII*2 at a starting
concentration of 6,000 IU/ml was used as a positive control (p) ; back-
ground (O) . Each titration represents the supernatant ofa culture ofcells
obtained from an individual rat. The experiment was repeatedwith similar
results .
poorly to rIL2 compared with cells from grafts that were
undergoing rejection in naive recipients . Interestingly, how-
ever, cells isolated from tolerant animals showed an early very
low response to IL2 at a time at which cells from untreated
rats were unable to respond to IL-2 (Fig . 4 b) . As a specificity
control for the observed effects on the IL-2R expression, graft-
infiltrating cells were isolated from rats that had been preoper-
atively transfused with third-party blood and therefore will
reject their grafts acutely (14), and tested for their ability to
Figure 7.
￿
Tolerant rats express the IL2 gene. Expression of the IL2
gene was assessed in RNA isolated from the grafts of tolerant (T), non-
tolerant (NT), and syngeneically transplanted (S) rats, 5 d after grafting,
using the PCR . m, marker track (kb ladder) ; n, no cDNA control . 15
,al samples of the amplified cDNA (60 cycles) were electrophoresed on
ethidium bromide containing 1.0% agarose gels and visualized underUV
illumination . The experiment was repeated on several occasions usingRNA
isolated from two individual groups of animals with essentially the same
results.Figure 8 .
￿
Semiquantitative analysis of the level of 11,2
expression . The level of IL-2 mRNA expression was as-
sessed semiquantitatively usingPCRfollowedby dot blot
analysis. (a) RNA was isolated from grafts 1 (columns
1, 4, and 7), 3 (columns 2, 5, and 8), or 5 (columns 3,
6, and 9) d after transplantation from syngeneic, (syn),
nontolerant (NT), or tolerant (T) rats and amplifiedusing
IL2 primers. Dot blots were hybridized with a third 11,2
primer which lies internal to the original two primers in
the rat 11,2cDNA sequence . (b) As a control for quanti-
tation, cDNA synthesis was performed using 0.1, 1, 10,
or 100 !&gRNA from nontolerant animals and amplified
and dot-blotted as in a using 11,2 primers . Under these
experimental conditions 10-fold differences in target se-
quence are easily distinguishable . (c) ControlPCR using
primers and internal oligonucleotide for hybridization to
the dot blot derived from the rat cytoplasmic 0-actin sequence . Samples are presented in the same order as in a ; n, no cDNA negative control . Samples
of RNA used here are shown in Fig . 3 C . These experiments have been repeated on five different occasions using RNA isolated from two groups
of animals with the same result.
respond to 11,2 . Fig. 5 shows that cells isolated from such
animals, 3 d after transplantation, respond poorly to IL2 (Fig .
5 b), but develop a good IL2 response by day 5 (Fig . 5 a) .
Thus the reduced IIr2R expression is confined to the cells
of tolerant rats .
Tolerant Animals Are Unable to Make Biologically Active
11,2. It is known that the presence of IL-2 upregulates the
expression of its receptor (23) . It was therefore possible that
the low Ilr2R expression and poor response to IL2 of cells
from tolerant animals was due to an inability of such rats
to make IL2 . Graft-infiltrating cells from tolerant animals
were restimulated with alloantigen in culture and the super-
natants of such cultures tested for the presence of biologi-
cally active IL2 . We were unable to detect any 11,2 activity
in the cultures of cells from tolerant rats (Fig. 6) .
Tolerant Animals Express 11,2 mRNA .
￿
We next examined
whether the defect in IL2 production was reflected by the
level ofmessenger RNA induction . Amplification using RNA
in the PCR from both tolerant and nontolerant animals
resulted in a product of the predicted size for IL-2 (Fig . 7) .
Further, this product was positive when a Southern blot of
the amplified DNA was probed with a third oligonucleotide
whose position in the cDNA sequence lay between that of
the original two primers . As a control, we usedRNA from
a syngeneic transplant which was negative in thePCR (Fig .
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Figure 9 .
￿
Administration of 11,2 at the time oftransplantation prevents
the induction of tolerance. Animals were treated and transplanted as usual.
On the day of transplantation and for the subsequent 5 d, animals received
intraperitoneal injections of rIL2 diluted in RPMI containing 10% FCS
and antibiotics . Animals were given 60 x 10 4 (O), 30 x 104 (0), 15
x 104 (" ) and 7 .5 x 104 (/) U 11,2 per day (9, 8, 8, 8 animals per
group, respectively) . Rats given medium alone or medium with IL2 ex-
cipient control buffer survived indefinitely (six animals) (" ) . DA rats trans-
planted withDA kidneys and treated with 60 x 104 U 11,2 per day sur-
vived indefinitely (five animals) (,&) . The results are pooled data from 10
different experiments.7). Since we used the PCR for these analyses, it is difficult
to exclude absolutely the possibility that there may be quan-
titative differences in the levels of 1162 mRNA in tolerant
and nontolerant animals. However, our data (Fig. 8 a) repeating
the analyses under limiting conditions suggests that this is
not the case since we always find similar levels of product
even when using few cycles of amplification with low levels
of starting RNA. As may be seen from Fig. 8 b, these condi-
tions alloweasy discrimination of samples containing 10-fold
differences in target sequence. Amplification ofidentical cDNA
samples from rejected and nonrejected transplants using
primers for cytoplasmic /3 actin as a control shows equal levels
of product in all cases (Fig. 8 c).
Tolerance Induction Is Abrogated by the Systemic Administra-
tion of IL2. We hypothesized that if the tolerant animals
were unable to reject their grafts simply because they were
unable to produce IL-2, it should be possible to abrogate the
induction of tolerance by injection of IL-2 into animals at
the time of transplantation. This approach is not unprecedented
since Malkovsky et al. (24) were able to diminish neonatally
induced allograft tolerance in vivo by injection of IL2. Fig.
9 shows that even relatively low doses of systemically ad-
ministered IL-2 completelyabrogated the induction of toler-
ance and the animals acutely rejected their transplants. This
effect was not due to nonspecific toxicity of the IL2, since
animals transplanted with a syngeneic graft and treated with
IL-2 at the highest dose survived indefinitely with normal
renal function. It seems unlikely that this treatment induced
any additional or alternative routes of graft rejection, e.g.,
LAK cells, since the doses of IL-2 used are much lower than
that normally required to induce this activity.
Discussion
Thus we have demonstrated that a mixed stateofunrespon-
siveness exists in these alloantigen-pretreated, graft-tolerant
animals. These animals possess donor-specific cytotoxic cells
and make some cytokines in response to alloantigen indicating
that, in this model, deletion of specific alloreactive cells, if
it occurs at all, cannot be complete. However, we have shown
that the IL-2 pathway is abnormallyregulated in these animals.
IL-2R expression is decreased because of low expression of
both the IL2R a and a chain genes and this is reflected in
a decreased ability of cells to respond to IL-2. This appears
to be due to a lack of production of biologically active IL-2
although the IL-2 gene is induced. Indeed, the induction of
tolerance may be reversed by the administration of IL-2 to
rats at the time of grafting. These data imply that the defect
in alloantigen-pretreated animals lies in their inability to pro-
duce biologically active IL-2 which in turn results in abnormal
IL2R expression.
Interestingly, it appears in our model that both the initial
injection of blood and the transplant are required for toler-
ance induction since animals given a third party transfusion
before transplantation do not show a similar inhibition of
the IL-2 response. It seems likely that a primary signal for
activation ofT cells occurs in this model since there is appar-
ently normal 11,2 gene and low 1L2R gene induction. It is
85
￿
Dallman et al.
possible that a secondary signal required for full and sustained
T cell activation is, however, missing.
At what level regulation of 11,2 production occurs is not
quite clear. Expression of the IL -2 gene clearly occurs, since
the PCR analysis does not detect 11,2 gene expression in resting
lymphocytes (Dallman, M.J., unpublished results) or, as shown
above, in syngeneic transplants. These data therefore give rise
to the intriguing possibility that there maybe abnormal trans-
lational control of IL-2 production in the tolerant animals,
although no such regulation has previously been described
for the IL-2 gene. It is also possible that the mRNA we ob-
serve is not in a mature form. Since the structure of the rat
11,2 gene is unknown, this cannot be formally excluded. How-
ever, the PCR primers used span 3 introns ofboth the mouse
and human IL-2 genes (25, 26) and therefore it seems un-
likely, given the size of the 11,2 product found in these ex-
periments, that the product is derived from unspliced RNA.
Lastly, it is possible that the tolerant animals make functional
IL-2 protein but that they simultaneously make an IL-2 an-
tagonist resulting in our inability to observe functional IL-2
activity in the in vitro system. Such an example of a cytokine
antagonist has recently been defined for IM and its receptor
(27, 28). We are currently investigating all of these possibilities.
Inhibition of the 11,2 pathway may be involved in toler-
ance induction where T cell anergy has been implicated; this
has previously been alluded to by other workers, both when
the antigen is presented neonatally (in neonatal tolerance or
transgenic models; references 1, 6, 10, 29, and 30) and to
adult animals (9). However, none of these studies examine
IL-2R a and a chain expression and the functional conse-
quences of such expression together with an analysis of IL-2
at both the gene and protein levels. Further, only the work
of Malkovsky et al. (1) has shown any effect of IL-2 ad-
ministered to mice in the reversal of neonatal tolerance, but
the data were in contrast to those of Tempelis et al. (31) in
another model of neonatal tolerance.
The regulation of the IL2 pathway demonstrated in this
animal model oftolerance induction does bear a striking resem-
blance to the T cell anergy that has been induced in cell cul-
ture systems (32-35) . In these systems, it has been suggested
that T cell anergy results after antigenic stimulation in the
absence of a second signal. The nature of this second signal
is unclear but appears to require cell-cell contact and acts
via nonconventional signal transduction mechanisms (35). A
good candidate for such a signaling mechanism is the CD28
molecule which does not appear to signal either through cal-
cium flux or activation of protein kinase C and requires a
primary signaling event through either the CD3/TCR or
CD2 proteins (36, 37) . Activation through this molecule in-
creases both the rate of transcription and mRNA stability
of a number of cytokine genes, including IL-2 (38). The role
of CD28 signaling in our model oftolerance is currently under
investigation.
Recently, the inhibition ofcytokine synthesis by Thl cells
has been reported to occur through the elaboration ofcytokine
synthesis inhibitory factor by Th2 cells (39) . This protein
does not inhibit production of cytokines by Th2 cells. Thus
production of IFN--y is reduced but of 11,4 and IL-5 isunaffected. However, secretion oflymphokines produced early
during the response of Th1 cells, such as IL2 and TNF-f3,
is not, or is only minimally, affected. Further, this cytokine
appears to act by preventing cytokine gene transcription. It
thus seems unlikely that theelaboration ofcytokine synthesis
inhibitory factor couldbe responsible for the IL2regulation
observed in our model of tolerance. However, we are cur-
rently developing PCR for the analysis of rat 11,4 and
TNF-(3 to further investigate this possibility.
It is important to note that, in clinical practice, preopera-
tive, donor-specific blood transfusion has also been shown
to improve survival ofrenal allografts between 1 and 2 HLA
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haplotype-disparate, living, related donors andrecipients (40).
Whether or not similar regulation of the 11,2 pathway is in-
volved in this clinical setting remains to be seen. With re-
spectto this issue, immunosuppressive strategies that directly
interferewith the IL2pathway, such as theuse of cyclosporin
A (41) and mAbs that react with the IL2R (42), have been
effective immunosuppressive agents in clinical transplanta-
tion. It is apparent then that specific regulation of the im-
mune response at thelevel of the 11,2 pathway has profound
implications for the induction of peripheral tolerance to al-
loantigens.
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